Our Life Science Deal Flow PDUFA Trade Strategy is not applicable to just any approaching date. There are several dates this month; Celgene’s (Nasdaq: CELG) istodax®, for relapsed and refractory peripheral T-cell lymphoma, Acura Pharmaceutical’s (Nasdaq: ACUR) acurox®, an abuse-resistant pain med, and Fibrorcell Science’s (Nasdaq: FCSC) iaviv®, for the treatment of moderate to serve nasolabial folds and wrinkles. None of these entities have passed our filters to approve the trade. So though we have an itchy trigger finger and are eager to put some of our Optimer (Nasdaq: OPTR) winnings to work, patience is critical.

There are a number of gating elements that clear an entity to put on the PDUFA trade.

We are excited to now be queuing up the next deal. Our selection will be revealed in a separate post. In addition, a Profit.ly account will be turned on so that there will be third-party public validation of our performance.